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Adipocytes are a signiﬁcant component of the bone marrow microenvironment. Although bone marrow
adipocytes were ﬁrst identiﬁed more than 100 years ago, it is only in recent years that an understanding
of their complex physiological role is emerging. Bone marrow adipocytes act as local regulators of ske-
letal biology and homeostasis, with recent studies suggesting that marrow adipose tissue is metabolically
active, and can function as an endocrine organ. As such, bone marrow adipocytes have the potential to
interact with tumour cells, inﬂuencing both tumour growth and bone disease. This review discusses the
current evidence for the role of bone marrow adipocytes in tumour growth within the bone marrow
microenvironment and the development of the associated bone disease.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Bone marrow adipocytes are one of the most abundant cell
types found in bone marrow tissue. They constitute approximately
15% of the bone marrow volume in young adults, rising to 60% by
the age of 65 years old [1]. Previously considered as inert space
ﬁlling cells with little biological signiﬁcance, accumulating evi-
dence demonstrates that bone marrow adipocytes are more than
just passive bystanders of the marrow. They have a distinctive
phenotype, which resembles both brown and white adipose tissue
and are now recognised to have specialised functions [2]. They
store and secrete fatty acids, cytokines and adipokines among
them leptin and adiponectin, which regulate calorie intake and
insulin sensitivity, respectively. Morphologically bone marrow
adipocytes are smaller in size than their visceral counterparts;
however the net effect of fatty acid uptake is similar due to en-
hanced triacylglycerol synthesis. They have the potential to inﬂu-
ence neighbouring cells by autocrine, paracrine and endocrine
signalling making them a powerful player in inﬂuencing the bone
microenvironment as a whole. Marrow adipocytes and osteoblasts
share common progenitor cells, known as bone marrow me-
senchymal stromal cells (MSCs) [3]. Their lineage commitment is
thought to be regulated by adipogenic and osteogenic factors in
the bone microenvironment that activate their respective tran-
scriptional programs. However, in recent years the identiﬁcation ofGmbH. This is an open access art
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added another level of complexity. The balance between these two
cell types appears to play a pivotal role in bone homeostasis and so
when the scales are tipped in favour of adipogenesis then by de-
fault osteoblastogenesis is negatively regulated. Moreover, there is
a building body of evidence to suggest that a subpopulation of
adipocytes are generated from bone marrow myeloid cells, posing
the question as to how these differ in their function and behaviour
to adipocytes generated from MSCs [4]. Furthermore, bone marrow
adiposity is also known to inhibit haematopoiesis [5]. There is con-
siderable evidence to support a metabolic role for marrow adipocytes
however their inﬂuence on the development and progression of me-
tastatic bone disease is only now becoming apparent.2. Bone marrow adipocytes in the tumour-bone
microenvironment
The bone provides a unique and supportive microenvironment
for a number of solid tumour metastases including breast, prostate
and the haematological malignancy multiple myeloma [6]. Cancer
cells that intrude into this microenvironment produce various
cytokines and growth factors which dysregulate the normal cou-
pling of osteoclasts and osteoblasts. The increased bone resorption
releases a number of factors which act positively upon the cancer
cells thus perpetuating a “vicious cycle”, a feed-forward cycle that
is critical to the establishment of bone metastasis. However, it
would be short sighted to think that bone metastases only im-
pinge upon osteoblasts and osteoclasts, as there are many more
cells residing in the bone marrow such as ﬁbroblasts, macrophagesicle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Adipocytes within the tumour-bone microenvironment. The relationship between tumour cells and bone cells is well documented, whereby tumour cells promote
osteolytic bone disease and resorbed bone releases factors to promote tumour growth and survival. Adipocytes are ideally placed to interact with this relationship, with
evidence to support both pro- and anti-tumour effects, and feedback from tumour cells to bone marrow adipocytes.
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Bone metastatic cancers primarily occur in older patients whose
bone marrow is heavily populated by adipocytes [7]. In recent
years there has been building interest in the contribution of
marrow adipocytes to metastatic disease. In breast, multiple
myeloma (MM) and prostate there is demonstrable evidence that
marrow adipocytes attract and interact with cancer cells, however
the advantages these interactions bestow are still open to debate.
Diet-induced obesity has been shown to promote development of
a myeloma-like condition, and to increase prostate cancer-induced
bone disease [8–10]. Cancer cells are attracted to adipocytes within
the metabolically active red marrow of the bone and these adi-
pocytes interact closely with their neighbouring cells [9, 11–13].
These observations suggest that an adipocyte-rich environment
could fuel disease by creating a permissive favourable niche for
cancer cells to establish and progress.
Both breast cancer and MM cause osteolytic lesions, inhibiting
osteoblast differentiation and thereby tipping the balance in fa-
vour of osteoclastic activity. In contrast, prostate cancer pre-
dominantly causes osteoblastic bone disease. Interestingly, in-
creased marrow adiposity has been associated with both osteolytic
and osteoblastic disease [8,10,14]. However, one crucial factor
these two processes have in common is the need for energy.
Adipocytes are ﬁlled with numerous lipid droplets which serve as
an effective source of fatty acids when metabolic demand is in-
creased. Podgorski and colleagues demonstrated that lipids can be
trafﬁcked between adipocytes and cancer cells fuelling tumour
growth and invasiveness by upregulating FABP4, IL-1β and HMOX-1 in the metastatic tumour cells [9]. Adipocytes also support
cancer cells in an endocrine manner, secreting growth factors,
adipokines and chemokines that lead to tumour survival. In MM
factors such as IL-6, TNF-α, CXCL12 and leptin play a role in disease
establishment and progression promoting cell proliferation and
migration as well as preventing apoptosis [11,15]. In prostate
cancer the chemokines CXCL1 and CXCL2 have been implicated in
promoting tumour associated bone disease by upregulating os-
teoclastogenesis, and in turn promoting tumour cell survival [10].
Recently, breast cancer cells have been shown to be recruited to
bone marrow adipose tissue by the secretion of IL-1β and leptin
[16]. The abundance of marrow adipocytes in ageing bones may
increase the fertility of the bone microenvironment by providing a
constant source of energy and growth factors for cancer cells to
thrive and progress in these skeletal sites. However, the identiﬁ-
cation of bone marrow adipocytes as a major source of circulating
adiponectin [17], greater than white adipose tissue, raises the
possibility that bone marrow adipocytes may also have anti-tu-
mour functions due to the tumour-suppressive effects of
adiponectin.3. Cancer-associated adipocytes
Adipocytes located in close proximity to invasive cancer cells in
the primary tumour exhibit profound phenotypic changes that
include both morphological and functional alternations and are
often referred to as cancer-associated adipocytes (CAAs). The
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lipid content (delipidation) and acquisition of a ﬁbroblast-like/
preadipocyte phenotype (de-differentiation). Functionally they
exhibit a decrease in expression of adipocyte-related genes such as
adiponectin, FABP4 and resistin coupled with an increase in the
production of pro-inﬂammatory cytokines IL-6, IL-1β [9,18]. These
changes were primarily reported in breast cancer studies in as-
sociated with white adipose tissue, however recent in vitro work
suggests these changes are also important in the bone marrow [9].4. Targeting adipocytes
Given the potential tumour-supporting role of adipocytes, tar-
geting these cells either alone or in combination with common
therapeutics may be a promising approach. Modulating levels of
adipokines such as adiponectin has been shown to exert an anti-
tumour effect. Pharmacological enhancement of circulating adi-
ponectin by the apolipoprotein mimetic L-4F was shown to cause
cancer cell death in mouse models of myeloma [19]. Due to the
increasing importance of lipid metabolism in tumour cell survival,
drugs have been developed that target essential molecules of fatty
acid synthesis and uptake. Chemical or RNAi-mediated inhibition
of key enzymes involved in fatty acid synthesis, including fatty
acid synthase (FASN) [20], acetyl-CoA-carboxylase and ATP-citrate
lyase has been shown to attenuate tumour cell proliferation and
induce cell death in a number of different cancer cell lines and
mouse models [21]. Approaches that regulate the balance between
adipogenesis and osteogenesis may also be effective in maintain-
ing healthy bone homeostasis thereby preventing cancer inﬁltra-
tion. Modulation of the nuclear receptors, glucocorticoid receptor
and PPARγ and their respective pharmacological ligands, corti-
costeroids and thiazolidinediones, directly regulate osteogenic
versus adipogenic differentiation of MSCs [22] and so could be
targeted accordingly. Another such target is protein kinase C
which also promotes osteogenesis and has anti-tumourigenic
properties [23]. Investigating these treatment strategies more
closely may provide new insight in to which pathways are being
exploited by cancer cells in order to evade conventional treat-
ments. Targeting adipocytes as part of a combination therapy may
prove to be a valuable tool, however a greater understanding be-
tween the balance of tumour-promoting and tumour-suppressive
effects of bone marrow adipocytes is required.5. Conclusions
Over the last few decades the contribution of adipocytes to
disease establishment and progression has become clearer. With
aging and obesity resulting in increased numbers of bone marrow
adipocytes, it is important to further understand the inﬂuence
these cells are having on their environment. Targeting adipocytes
and their products may open new therapeutic avenues in the ﬁght
against lethal metastatic cancers.Acknowledgements
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